Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 4/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | RCE1 | Q9Y256 | 8/20 | 0.92 |
| ▸ | TP53 | P04637 | 4/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955655 | 0.91 | RCE1 (0.83) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL14955656 | 0.91 | RCE1 (0.83) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL14961225 | 0.88 | RCE1 (0.79) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL11955293 | 0.86 | P4HB (1.00) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL12905275 | 0.85 | P4HB (0.74) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL12064843 | 0.84 | RCE1 (0.72) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL23359134 | 0.84 | RCE1 (1.00) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL31741895 | 0.84 | RCE1 (1.00) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL31741894 | 0.84 | RCE1 (1.00) | P4HBHSP90AA1RCE1TP53CYP2C9 | |
| SCHEMBL29962903 | 0.84 | RCE1 (1.00) | P4HBHSP90AA1RCE1TP53CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566849-B1 | 8-HYDROXY-QUINOLINE DERIVATIVES | AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) | 2019-09-18 | — | — | EP | disclosed |
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR (US) | 2019-08-22 | — | — | US | disclosed |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-05-28 | — | — | US | disclosed |
| US-9273031-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273031-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9238641-B2 | — | — | 2016-01-19 | — | — | US | disclosed |
| US-9238641-B2 | — | — | 2016-01-19 | — | — | US | disclosed |
| CN-102985407-B | 8-hydroxy-quinoline derivatives | "AVIDIN" KUTATO, FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG (HU) | 2015-09-09 | — | — | CN | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130131096-A1 | 8-HYDROXY-QUINOLINE DERIVATIVES | UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) | 2013-05-23 | — | — | US | disclosed |
| EP-2566849-A1 | 8-HYDROXY-QUINOLINE DERIVATIVES | "Avidin" Kutató, Fejleszt És Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) | 2013-03-13 | — | — | EP | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011148208-A1 | 8-HYDROXY-QUINOLINE DERIVATIVES | "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| WO-2009151972-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | P4HB 4025/4885HSP90AA1 356/4885RCE1 1354/4885 |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | P4HB 2320/4885HSP90AA1 961/4885RCE1 504/4885 |
| US-20130131096-A1 | 8-HYDROXY-QUINOLINE DERIVATIVES | CYP2C8, NQO1, KEAP1 | P4HB 1817/4885HSP90AA1 3406/4885RCE1 1086/4885 |
| US-10301265-B2 | Small molecule inhibitors of botulinum neurotoxins | RAC2, BTN3A1, GDI1 | P4HB 2999/4885HSP90AA1 2599/4885RCE1 314/4885 |
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | P4HB 2999/4885HSP90AA1 2599/4885RCE1 314/4885 |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | P4HB 2999/4885HSP90AA1 2599/4885RCE1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.